Diansong Zhou

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Liver Metastases

Clinical Evaluation

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

British journal of clinical pharmacology

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
KyoungSoo Lim, Xu Sue Zhu, Diansong Zhou, Song Ren, Alex Phipps
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology. Clinical pharmacology and therapeutics 116 (2) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
KyoungSoo Lim, Xu Sue Zhu, Diansong Zhou, Song Ren, Alex Phipps
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology. Clinical pharmacology and therapeutics (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Xuyang Song, Robin Kate Kelley, Michelle L Green, Nathan Standifer, KyoungSoo Lim, Diansong Zhou, James Dunyak, Alejandra Negro, John F Kurland, Song Ren, Anis A Khan, Megan Gibbs, Ghassan K Abou-Alfa
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients With Unresectable Hepatocellular Carcinoma. Clinical pharmacology and therapeutics (2023)
Jimmy Zhijian He, Vincent Duval, Petra Jauslin, Antonio Gonçalves, Aburough Abegesah, Chunling Fan, KyoungSoo Lim, Xuyang Song, Cecil Chen, Xiaojin Shi, Helen Mann, Lee Krug, Song Ren, Alex Phipps, Megan Gibbs, Diansong Zhou
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clinical pharmacology and therapeutics (2023)
Michael Hwang, Yen Lin Chia, Yanan Zheng, Cecil Chi-Keung Chen, Jimmy He, Xuyang Song, Diansong Zhou, Sarah B Goldberg, Lillian L Siu, David Planchard, Solange Peters, Helen Mann, Lee Krug, Caroline Even
Population Pharmacokinetic Modeling of Tremelimumab in Patients with Advanced Solid Tumors and the Impact of Disease Status on Time-varying Clearance. British journal of clinical pharmacology (2022)
Mark McAllister, Talia Flanagan, Susan Cole, Andreas Abend, Evangelos Kotzagiorgis, Jobst Limberg, Heather Mead, Victor Mangas Sanjuan, Paul A Dickinson, Andrea Moir, Xavier Pepin, Diansong Zhou, Christophe Tistaert, Aristides Dokoumetzidis, Om Anand, Maxime Le Merdy, David B Turner, Brendan T Griffin, Adam Darwich, Jennifer Dressman, Claire Mackie
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. Pharmaceutics 14 (5) (2022)
Diansong Zhou, Buyun Chen, Shringi Sharma, Weifeng Tang, Xavier Pepin
Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib. Pharmaceutical research (2022)
Xuyang Song, Robin Kate Kelley, Anis A Khan, Nathan Standifer, Diansong Zhou, KyoungSoo Lim, Rajesh Krishna, Lucy Liu, Kun Wang, Patricia McCoon, Alejandra Negro, Philip He, Megan Gibbs, John F Kurland, Ghassan K Abou-Alfa
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Buyun Chen, Diansong Zhou, Hua Wei, Marmor Yotvat, Li Zhou, Jean Cheung, Nicole Sarvaria, Richard Lai, Shringi Sharma, Karthick Vishwanathan, Joseph Ware
Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British journal of clinical pharmacology 88 (8) (2022)
Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Alienor Berges, Tsveta Milenkova, Nidal Al-Huniti, Helen Tomkinson, Hongmei Xu
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Clinical pharmacology and therapeutics 105 (6) (2019)
Xiao Tong, Hongmei Xu, David J Carlile, Helen Tomkinson, Nidal Al-Huniti, Diansong Zhou
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer. Journal of clinical pharmacology 59 (1) (2018)
Wangda Zhou, Helen Humphries, Sibylle Neuhoff, Iain Gardner, Eric Masson, Nidal Al-Huniti, Diansong Zhou
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharmaceutics & drug disposition 38 (6) (2017)
Parul Patel, Eleanor Howgate, Paul Martin, David J Carlile, Leon Aarons, Diansong Zhou
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. British journal of clinical pharmacology 84 (1) (2017)